1-0_HOME-LANDING_CAROUSEL-4

In collaboration with ACD’s COVID-19 Taskforce, College continues to ensure that sensible and appropriate advice is delivered to Fellows, trainees and patients. Information will be updated as developments occur.

College encourages Fellows to stay up to date with government advice and apply this practically. For the most updated COVID-19 information, please refer to the Department of Health website or your relevant State/Territory website.

COVID-19 Vaccination

Latest updates (as of July 26th, 2021)

  • On 17 June 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) recommended Comirnaty (Pfizer) as the preferred vaccine for those aged 16 to under 60 years except in circumstances where the benefit is likely to outweigh the risk and where informed consent has been obtained. 
  • For people aged 60 years and above, ATAGI advised the benefit of preventing COVID-19 with COVID-19 vaccine AstraZeneca outweighs the risk of thrombosis with thrombocytopenia syndrome (TTS).  
  • ATAGI also advised that people of any age without contraindications who have had their first dose of COVID-19 Vaccine AstraZeneca without any serious adverse events should receive the second dose.
  • The Federal Government has expanded access to the AstraZeneca vaccine to adults under 40, with informed consent.
  • On 21 July 2021, ATAGI advised that there is no update to its statement of 17 June 2021, however adults under 60 years old should, in the context of a COVID outbreak and where supply of the Pfizer vaccine is constrained, reassess the benefit of being vaccinated with the AstraZeneca vaccine, versus the rare risk of a serious side effect.
  • On 24 July 2021, ATAGI issued a statement in response to the NSW COVID-19 outbreak recommending that all individuals aged 18 years and above in greater Sydney, including adults under 60, should strongly consider getting vaccinated with any available vaccine including with the AstraZeneca vaccine.

The current recommendations on the use of the COVID-19 vaccine, AstraZeneca, provided by the Australian Technical Advisory Group on Immunisation (ATAGI) are available here:

ATAGI statement: Response to NSW COVID-19 outbreak – 24 July 2021ATAGI24 Jul 2021
ATAGI update following weekly COVID-19 meeting – 21 July 2021 (External link)ATAGI21 Jul 2021

ATAGI statement on use of COVID-19 vaccines in an outbreak setting (External link)

ATAGI13 Jul 2021
Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca (Patient information. External link)Department of Health30 Jun 2021
ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca (External Link)ATAGI17 Jun 2021
ATAGI and the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) joint statement: Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of the COVID-19 Vaccine AstraZeneca (External link)ATAGI/THANZ23 May 2021

For the latest information on COVID-19 vaccinations, visit the Department of Health’s COVID-19 vaccination website, You can also subscribe for the COVID-19 vaccination updates.

College has also developed some COVID-19 information for patients, including COVID-19 vaccinations.

Guidance on COVID-19 vaccinations in dermatology patients on immunomodulatory and biologic agents was published in the Australasian Journal of Dermatology in March 2021. 

The article by the Australasian Medical Dermatology Group makes preliminary recommendations around COVID-19 vaccination in these patients. 

In summary:

  • Vaccination against COVID-19 is strongly encouraged for all patients on immunomodulatory drugs and/or biologic agents.
  • There is currently insufficient data to recommend one COVID-19 vaccine or vaccine type over another.
  • No specific additional risk in patients on immunomodulatory or biologic therapies has so far been identified.
  • Data on vaccine efficacy in patients on these therapies is missing, so standard vaccination protocols are recommended until otherwise advised.

Resource

Source

Updated

SARS‐CoV‐2 (COVID‐19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group (External Link)

Australasian Journal of Dermatology

30 Mar 2021

COVID-19 provider guide for patients with immunocompromise (External Link)

ATAGI

18 Jun 2021

COVID-19 vaccination decision guide for people with immunocompromise (For patients. External Link)

ATAGI

18 Jun 2021

COVID-19 vaccine information for people on an immunosuppressive or biological treatment (For patients. PDF)

Skin Health Institute

Mar 2021

COVID-19 vaccination for pregnant women: Joint Statement between the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) and ATAGI (External Link)

RANZCOG & ATAGI

9 Jun 2021

Clinical Care and Service Provision

Resource

Source

Updated

COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement (Wang C et al. Australasian Journal of Dermatology)

ACD

9 Apr 2020

COVID-19 – Information for patients receiving immunosuppressive medication (Patient factsheet, PDF)

ACD

24 Mar 2020

COVID-19 – Information for patients receiving biologic medication (Patient factsheet, PDF)

ACD

24 Mar 2020

Guidance on the use of immunosuppressive agents during COVID-19 (External link)

American Academy of Dermatology

Ongoing

Department of Health – Definition of people at risk for serious illness from COVID-19 (External link)

Federal Department of Health

Ongoing

COVID-19 advice for people with chronic health conditions (External link)

Federal Department of Health

Ongoing

Resource

Source

Updated

Practice Environment Guidance (PDF) covering signage, reception, waiting room and doctors’ rooms set up, PPE, cleaning and staff reminders.

ACD

30 Apr 2020

Guidance on the safe use of Laser & Energy Based Devices taking into consideration COVID-19/SARS-CoV-2 (PDF)

Australasian Society of Cosmetic Dermatologists

26 Apr 2020

Guidance on infection control and plume management with Laser and Energy-Based Devices taking into consideration COVID-19 (Sullivan JR et al, Australasian Journal of Dermatology)

AJD

19 Aug 2020

Discontinuation of Transmission-Based Precautions and Disposition of Patients with SARS-COVID-2 Infection in Healthcare Settings – Interim Guidance (External link)

US Centers for Disease Control and Prevention

Ongoing

Keep your face healthy during COVID-19: Tips to avoid skin problems and allow you to keep wearing a mask (Factsheet for staff and patients, PDF)

ACD and Skin Health Institute

31 Jul 2020

Keep your face healthy during COVID-19: Tips to avoid skin problems and allow you to keep wearing a mask (Poster, PDF)

ACD and Skin Health Institute

31 Jul 2020

Resource

Source

Updated

Clinical Service Provision guidance (PDF) including continuity of care, consultations, prescriptions, letters and referrals, phototherapy, immunosuppressive and biologic medications.

ACD

20 Apr 2020

Delivering care by telehealth (ACD webpages)

ACD

Ongoing

MBS COVID-19 Telehealth items (External link)

MBS OnlineOngoing

Providing health care remotely during COVID-19 (External link) includes telehealth services, prescriptions, home delivery of medicines.

Federal Department of HealthOngoing

The following third-party information has been provided without charge and is high level and general in nature. College strongly recommends Fellows seek specific guidance from their own accountants, advisers and indemnity groups who can tailor advice to their particular practice, financial position and business model.

Resource

Source

Updated

Practice Staff Working Arrangements guidance (PDF) covering managing staff illness, staff potential or actual contact with COVID-19 case, staff entitlements, staffing levels, remote working, Australian Government support for businesses/employees.

ACD

30 Jun 2020

William Buck’s COVID-19 Resource Centre (External link) provides guidance on government subsidies and other financial matters and is specifically curated with business owners and operators in mind.  

William Buck (ACD’s current auditor)

Ongoing

Federal, State & Territory Government Links

College News – CPD & Training Program

The 2021 Training Program has commenced. Updated changes, including 2021 COVID-19 implications, are listed in CONNECT and in the handbook.

This information is subject to change. Please continue to visit this webpage and the ‘All Trainees’ CONNECT group (‘COVID update’ thread).

2021 Fellowship Examination

2021 Fellowship Examination Update (PDF)

ACD

16 Mar 2021

Trainee Wellbeing

The Trainee Wellbeing and Engagement teamwork to ensure that all trainees have a voice and receive the support they need throughout the training program.

Under the direction of Dr. Catherine Scarff, Engagement Officers Ashleigh Thomas (QLD and NSW) and Caterina De Meneghi (VIC, SA, WA, TAS and NT) provide support and advocacy to all trainees including IMGs and PTCs. They also have regular contact with Faculty Directors of Training and Supervisors and work closely with the Trainee Representative Committee to develop relevant initiatives for trainees and address concerns brought forward.

The Engagement Officers assist with reasonable adjustments and ensure that all communication with trainees is kept confidential.

Visit ACD’s Support webpage for more information.